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Abstract
Background: Some types of beta-human papillomavirus (b-HPV) may be one of the probable causes of squamous cell
carcinoma (SCC) in transplant recipients. b-HPVs are linked to SCC in the literature with small number of subjects.
Aim: Herein, the ﬁrst meta-analysis was carried out on the association between b-HPVs and cutaneous SCC in
immunosuppressed patients.
Methods: A systematic search was carried out in the PubMed and Scopus databases up to December 2018. The odds
ratio (OR) were calculated by RevMan 5.3 software and the event rate (ER) by Comprehensive Meta-Analysis 2.0 software with a 95% conﬁdence interval (CI).
Results: A total of 1250 records were identiﬁed through the two databases, but at last eleven studies were included in
the meta-analysis that they were published from 1989 to 2018. The results showed a signiﬁcantly high prevalence of bHPVs in cutaneous SCC patients (ER ¼ 69.1%; 95%CI: 58.7%, 77.8%). In addition, the prevalence of overall b-HPVs and
b-HPVs of 5, 8, 9, 17, 49, 75, and 76 in immunosuppressed cutaneous SCC patients was signiﬁcantly higher compared
with controls.
Conclusions: The ﬁndings of the present meta-analysis support the hypothesis that b-HPV may play a role in cutaneous
SCC development in immunosuppressed individuals.
Keywords: skin cancer, b-HPV, SCC, prevalence, immunosuppression, meta-analysis

1. Introduction

A

mong skin cancers, cutaneous SCC (cSCC)
is a quite common malignant proliferation
of the epithelial layers with an aggressive
behavior and possible metastasis [1]. The risk
factors for the SCC development are represented
by fair skin, intense sun-exposure, history of
sunburns, immunosuppression and beta-human
papillomavirus (b-HPV) infection. Indeed, one of
the probable causes of SCC is the HPV [2, 3].
HPVs are a great and various group of over 170

subsets with 5 main known HPV genera,
including Alpha, Beta (b), Gamma, Mu and Nu
papillomavirus [4, 5]. While other HPV genera
contribute to the formation of verruca vulgaris,
condyloma acuminate, and various types of anogenital cancers [6, 7], the b-genus appears to be
involved in human cutaneous carcinogenesis and
in promoting non-melanoma skin cancer development in immunosuppressed patients [8].
Among b-HPVs, HPVs 5 and 8 seem to have a
potential role in warts that may culminate in SCC
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formation [9]. Due to the high incidence of SCC in
organ transplant recipients in comparison with
the general population as well as the similarity of
their symptoms, clinical behavior and epidemiology with other virus-induced cancers (i.e.
Kaposi's sarcoma), some studies have focused on
their origin [10]. Among them, several studies
have demonstrated that a further increase in the
SCC appearance in transplant recipients is
correlated with a signiﬁcant degree of b-HPV
detection [11, 12]. It was reported that 90% of the
SCC lesions in Epidermodysplasia Verruciformis
patients - a rare genodermatosis determined by
multiple skin cancers on sun-exposed sites-were
found to increase the likelihood of viral carcinogenicity [13]. Recently, the association between bHPV and SCC in immunosuppressed patients has
been studied in several epidemiological studies
with controversial results [14, 15]. Considering the
hypothesis that b-HPV may play a role in cSCC
development in immunosuppressed individuals,
this meta-analysis was carried out to explore an
association between b-HPVs and cSCC in
immunosuppressed patients.

2. Materials and Methods
2.1. Identiﬁcation of studies
A systematic search was carried out in the
PubMed and Scopus databases up to December
2018 without any restrictions. To retrieve the
studies, one of authors (M.S) searched among two
databases with the search strategy of (“human
papillomavirus” or “HPV” or 00 b-HPV” or “betaHPV”) and (“cutaneous squamous cell carcinoma”
or “cutaneous SCC” or “skin squamous cell carcinoma” or “skin SCC” or “cSCC” or “nonmelanoma
skin neoplasms” or “nonmelanoma skin cancer” or
“squamous cell cancer” or “squamous cell
neoplasm”). In addition, the citations of the
retrieved studies in relation to the topic of our
meta-analysis were reviewed to ensure that no
studies were missed. After that, other authors (M.R
and F.B) assessed the relevant articles based on the
titles and abstracts. Subsequently, the articles with
the full-text meeting the criteria were screened.
After screening, the reasons for exclusion were
written for the studies removed and another
author (A.A) resolved the disagreements between
the authors.
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2.2. Eligibility criteria
The authors used the mentioned criteria for
selecting the studies. We included: 1) all types of
studies; 2) inclusion of immunosuppressed patients
of any age and gender; 3) diagnosis of cSCC established according to clinical and/or histologic criteria,
and 4) studies reporting the prevalence of b-HPVs in
cSCC patients. On the contrary, we excluded studies
with irrelevant or unavailable data, studies
including noncutaneous SCC, studies including
unspeciﬁed nonmelanoma skin cancer, animal
studies, duplicate studies, and conference papers,
case reports, and reviews.
2.3. Data abstraction
The data of the studies entered to the analysis
including ﬁrst name of ﬁrst author, publication year,
research area, study design, number of individuals
and b-HPV detection methods/subtypes, were
independently extracted and analyzed by three authors (M.S, M.R and F.B).
2.4. Statistical analysis
The values of odds ratio (OR) were computed by
Review Manager version 5.3 software and the event
rate (ER) by Comprehensive Meta-Analysis-version
2.0 software with a 95% conﬁdence interval (CI). To
estimate the pooled OR signiﬁcance, the Z test was
applied with a p-value (2-sided) < 0.05. In addition,
the I2 statistic was applied to estimate heterogeneity
that if P > 0.1 (I2<50%), there was a signiﬁcant heterogeneity and in this state, we used the ﬁxed-effects model; otherwise, the random-effects model
was used. The Funnel plots were analyzed with both
Egger's and Begg's tests that P < 0.05 (two-sided)
showed the signiﬁcant publication bias. To estimate
the stability of the pooled data, the sensitivity analyses (“cumulative analysis” and “the removal of one
study”) were applied.

3. Results
3.1. Study selection
A total of 1250 records were identiﬁed through the
two databases that after removing the duplicates,
775 records were screened, among which 748 irrelevant records were excluded (Fig. 1). Then, 27 fulltexts were evaluated, from among which 16 fulltexts were excluded with reasons (four reviews, two
animal studies, four studies not reporting b-HPV
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Fig. 1. Flow-chart of the study selection.

types, one reporting HPV in organ transplant recipients not affected by squamous cell carcinoma,
three reporting all HPV genera altogether (alpha,
beta, and gamma), and two reporting different skin
cancers altogether). At last, eleven studies were
entered to the analysis.

25], two were case-control [20,26] and three were
cohort [17,18,21] studies. The detection methods of
b-HPVs were the Polymerase Chain Reaction
(PCR) for eight studies [16,18,19,22-26], serology for
two studies [17,21] and PCR and serology together
for two studies [20].

3.2. Features of studies

3.3. Meta-analysis

Table 1 is illustrated the features of eleven
studies included in the meta-analysis published
from 1989 to 2018. Four studies were presented
from United Kingdom [16-19], two from the
Netherlands [20,21], one from Scotland [22], one
from the United States of America [23], one from
Ireland [24], one from Germany [25] and one was a
multicenter study (Queensland, Australia, and
Italy) [26]. Six studies were uncontrolled [16,19,22-

The pooled analysis of eleven studies reporting
the prevalence of b-HPVs in immunosuppressed
cSCC patients showed an ER of 69.1% (95%CI:
58.7%, 77.8%; p ¼ 0.001; I2 ¼ 87.7% (Ph or
Pheterogeneity<0.0001) (Fig. 2). The results showed a
signiﬁcantly high prevalence of b-HPVs in cSCC in
immunosuppressed patients.
Four case-control studies were analyzed for OR of
b-HPVs in immunosuppressed cutaneous patients
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Table 1. Characteristics of the studies included in the meta-analysis.
First author, year publication

Country

Design/Population

b-HPV Detection
Methods/Subtypes

Barr, 1989 [22]

Scotland

Harwood, 2000 [16]

United Kingdom

Arron, 2011 [23]

United States of America

O'Connor, 2001 [24]

Ireland

Stockﬂeth, 2004 [25]

Germany

Casabonne, 2009 [17]

United Kingdom

Mackintosh, 2009 [18]

United Kingdom

Uncontrolled
Case: 25
Uncontrolled
Case: 26
Uncontrolled
Case: 14
Uncontrolled
Case: 9
Uncontrolled
Case: 16
Cohort
Case: 119
Control: 425
Cohort
Case: 53

Proby, 2011 [20]

The Netherlands

Neale, 2013 [26]

Queensland, Australia, and Italy

PCR
HPV type 5/8
PCR
All beta HPV types
PCR
All beta HPV types
PCR
All beta HPV types
PCR
HPV types 5, 8
Serology
HPV types 5, 8, 9, 15, 17, 20, 23, 24, 36, 38,
49, 75, 76, 92, 93, 96
PCR
HPV types 5, 8, 9, 12, 14, 15, 17, 19e25, 36
e38, 47, 49, 75, 76, 80, 92, 93 and 96
PCR & Serology
HPV types 5, 8, 9, 15, 17, 20, 23, 24, 36, 38,
49, 75, 76, 92, 93, 96
PCR
HPV types 5, 8, 15, 20, 23, 24, 36, 38

Bouwes Bavinck, 2018 [21]

The Netherlands

Purdie, 2018 [19]

United Kingdom

Case-control
Case: 204
Control: 377
Case-control
Case: 179
Control: 318
Cohort
Case: 90
Control: 536
Uncontrolled
Case: 12

Serology
All beta HPV types
PCR
All beta HPV types

Abbreviations: PCR, Polymerase chain reaction; HPV, Human papillomavirus.

affected by SCC compared to controls (Figs. 3 and
4). The OR was 1.36 for overall b-HPVs [95%CI: 1.10,
1.69; p ¼ 0.005] without heterogeneity, 1.41 for HPV5
[95%CI: 1.11, 1.79; p ¼ 0.004] without heterogeneity,
1.38 for HPV8 [95%CI: 1.10, 1.74; p ¼ 0.005] without
heterogeneity, 1.38 for HPV9 [95%CI: 1.03, 1.86;
p ¼ 0.03; I2 ¼ 23% (Ph ¼ 0.26)], 1.42 for HPV17 [95%
CI: 1.08, 1.87; p ¼ 0.01] without heterogeneity, 1.44
for HPV49 [95%CI: 1.09, 1.92; p ¼ 0.01] without
heterogeneity, 1.42 for HPV75 [95%CI: 1.02, 1.97;
p ¼ 0.04] without heterogeneity, and 1.62 for HPV76

[95%CI: 1.16, 2.27; p ¼ 0.005] without heterogeneity.
In addition, the OR was 2.05 for HPV15 [95%CI: 0.69,
6.07; p ¼ 0.19; I2 ¼ 95% (Ph < 0.00001)], 2.23 for
HPV23 [95%CI: 0.52, 9.61; p ¼ 0.28; I2 ¼ 96%
(Ph < 0.00001)], 2.21 for HPV38 [95%CI: 0.83, 5.89;
p ¼ 0.11; I2 ¼ 94% (Ph < 0.00001)], 1.34 for HPV92
[95%CI: 0.78, 2.33; p ¼ 0.29; I2 ¼ 56% (Ph ¼ 0.13)], 1.62
for HPV20 [95%CI: 0.76, 3.46; p ¼ 0.22; I2 ¼ 88%
(Ph ¼ 0.0003)], 2.02 for HPV24 [95%CI: 0.85, 4.81;
p ¼ 0.11; I2 ¼ 91% (Ph < 0.0001)], 1.69 for HPV36 [95%
CI: 0.48, 5.97; p ¼ 0.42; I2 ¼ 96% (Ph < 0.00001)] and

Fig. 2. Event rate of the prevalence of b-HPVs in immunosuppressed patients with cSCC.
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Fig. 3. Forest plot of odds ratio of prevalence of some b-HPVs in immunosuppressed patients with SCC compared to healthy controls.
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Fig. 4. Forest plot of odds ratio of prevalence of other b-HPVs in immunosuppressed patients affected by SCC compared to healthy controls.
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Fig. 5. Funnel plot of the prevalence of b-HPVs in immunosuppressed patients with SCC.

1.14 for HPV93 [95%CI: 1.80, 1.63; p ¼ 0.45] without
heterogeneity. The results showed that the prevalence of overall b-HPVs and b-HPVs of 5, 8, 9, 17, 49,
75, and 76 was signiﬁcantly higher in immunosuppressed SCC patients than in controls.
3.4. Sensitivity analysis
Two sensitivity analyses mentioned in methods
were performed on the prevalence of b-HPVs in
immunosuppressed patients with SCC. We found
that the pooled ER did not alter; therefore, these
results conﬁrmed the stability of initial pooled data.
3.5. Publication bias
With regard to publication bias, Fig. 5 illustrates
the funnel plot of the prevalence of b-HPVs in
immunosuppressed patients affected by SCC. The
Begg's test revealed a bias between the studies
( p ¼ 0.035), but no Egger's test ( p ¼ 0.340).

4. Discussion
SCC is usually a very rapidly growing dangerous
tumor with the proliferation of keratinocytes [27,28].
Renal transplant recipients have an elevated incidence of HPV-related cancers [29-33]. The beta
genus comprises more than 50 b-HPVs [34]. Some
studies have linked b-HPVs to SCC, but many
studies have considered a small number of subjects
and/or samples and others have been uncontrolled.
The present meta-analysis evaluated the ER of bHPVs in immunosuppressed patients with SCC and
also the OR of b-HPVs among these patients in
comparison to controls. The results showed that the

prevalence of b-HPVs in such patients was signiﬁcantly higher and also the OR of some b-HPV genotypes was signiﬁcantly higher in patients than in
controls (overall b-HPVs and b-HPVs of 5, 8, 9, 17,
49, 75, and 76).
The studies have shown a high detection of HPV
in both precancerous lesions and SCC in renal
transplant recipients (81% to 91%) [35,36]. The bHPV prevalence in the studies included in the present meta-analysis was ranged from 50.9% to 93.3%;
similarly, among uncontrolled studies, it varied
from 50.9% to 88.9%. Among case-control [20,26]
and cohort studies [17,21], including immunosuppressed individuals with SCC, one cohort study [21]
based on serology and one case-control study [20]
including the individuals with b-HPV antibodies
showed a signiﬁcantly increased risk. Two other
studies [17,26] failed to illustrate signiﬁcantly a difference between the patients and controls. The
controversy between the results and the wide range
of outcomes may be due to using different methods
with different sensitivity and speciﬁcity.
A previous meta-analysis [37] showed that cSCCs
were more probably to carry b-HPV genotypes
compared to healthy skin, and there was an increase
in b-HPV prevalence in tumors of immunosuppressed subjects in comparison to immunocompetent subjects. Concerning differences in b-HPV
prevalence among different groups of patients,
Harwood et al. [16] reported a different detection
rate of 84% versus 27% between two groups of patients (immunosuppressed versus immunocompetent subjects), which was conﬁrmed by Stockﬂeth
et al. subsequently (75% vs. 37%) [18]. However,
another study [20] did not detect differences (51%
versus 52%) in viral detection among parafﬁn-
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embedded tumors from immunosuppressed and
immunocompetent subjects. The younger age of
immunosuppressed patients than immunocompetent individuals was suggested to explain such a
result. Accordingly, several studies [23,38-40] reported that immunosuppression and older age had
an association with the viral load and higher prevalence of b-HPV. In fact, it can be concluded that
considering the age of the patient along with immune status is important in a correct interpretation
of the results and predicting the outcome. Moreover, some studies have conﬁrmed HPVs 5 and 8 to
be more frequently detected in the SCC from organ
transplant recipients [25,41,42]. Two studies [18,43]
showed that b-HPV was detected in a greater proportion of frozen samples compared to parafﬁnembedded specimens. A study [44] using Southern
hybridization and type-speciﬁc PCR failed to detect
any HPV 5 and 8 in 30 cSCC samples. Another study
[45] did not identify any HPV-DNA in 28 non-genital SCCs from immunosuppressed renal allograft
recipients. The methodical differences and the
different clinical specimens can affect improved bHPV detection [25]. Therefore, the used techniques
(with their own different sensitivities) can explain
the different results, and it is also mandatory to pay
attention to such issues in b-HPV detection while
analyzing the data. Another issue to be considered
is the productive status of the virus versus the higher
DNA (or even its small fragments) detection rate
since this is of primary importance when investigating the role of b-HPVs in cutaneous
carcinogenesis.
Moreover, the studies reported that the sunexposed samples showed higher b-HPV DNA
prevalence in both immunosuppressed and immunocompetent individuals, which can help the theory
of a powerful interaction between ultraviolet (UV)
radiation and b-HPV presence [46-48]. Therefore,
both immunosuppression and UV radiation may
elevate the b-HPV activity that is able to promote
the development of cancer [25,49].
The present meta-analysis suffers from several
signiﬁcant limitations. First, few studies reported.
Second, most studies included a few number of
patients. Third, different methods were used for the
detection of b-HPVs. Fourth; there were differences
in the detected b-HPV genotypes. These limitations
and also the role of age, UV radiation, and
geographical origin of cases could affect the obtained results in terms of b-HPV prevalence and
also create a high heterogeneity across the included
studies.
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5. Conclusions
The ﬁndings of the present meta-analysis support
the hypothesis that b-HPV may play a main role in
the cSCC development in immunosuppressed subjects. The prevalence of b-HPVs in these patients
was 69.1%, and several genotypes (overall b-HPVs
and b-HPVs of 5, 8, 9, 17, 49, 75, 76, and 93) were
associated with an elevated risk of developing cSCC
in immunosuppressed subjects compared to healthy
controls. Notwithstanding, it should be noted that
demographic and environmental factors can affect
the b-HPV prevalence. We believe that further
studies are currently needed to include a great
number of participants from different geographic
areas. In order to conﬁrm our results, it is also
important to notice the b-HPV detection methods
and considered genotypes.
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